News
-
-
-
-
-
-
-
-
-
-
PRESS RELEASE
TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update
TuHURA Biosciences, Inc. provides a business update on its innovative cancer immunotherapy technologies, including IFx-2.0 Phase 3 trial for Merkel Cell Carcinoma, potential KVA12123 acquisition, and key management appointments